每經AI快訊，11月(yue)29日，藍帆醫療公(gong)(gong)告，全(quan)資子公(gong)(gong)司(si)(si)山東吉威醫療制品(pin)(pin)有限公(gong)(gong)司(si)(si)參加了(le)國家組(zu)織冠脈支架集(ji)中(zhong)(zhong)帶(dai)(dai)量采(cai)購(gou)(gou)協議期(qi)滿后接續采(cai)購(gou)(gou)申報信息公(gong)(gong)開大會，共有兩款(kuan)產(chan)品(pin)(pin)擬(ni)中(zhong)(zhong)標(biao)本(ben)次(ci)(ci)集(ji)中(zhong)(zhong)帶(dai)(dai)量采(cai)購(gou)(gou)。本(ben)次(ci)(ci)集(ji)中(zhong)(zhong)采(cai)購(gou)(gou)是國家組(zu)織的第二次(ci)(ci)冠脈支架帶(dai)(dai)量采(cai)購(gou)(gou)，相較于首(shou)(shou)次(ci)(ci)集(ji)采(cai)中(zhong)(zhong)標(biao)報價469元/條(tiao)(tiao)，公(gong)(gong)司(si)(si)本(ben)次(ci)(ci)擬(ni)中(zhong)(zhong)標(biao)報價大幅提(ti)升(sheng)至824元/條(tiao)(tiao)和845元/條(tiao)(tiao)，公(gong)(gong)司(si)(si)旗下EXCROSSAL支架成為(wei)首(shou)(shou)次(ci)(ci)集(ji)采(cai)中(zhong)(zhong)標(biao)產(chan)品(pin)(pin)中(zhong)(zhong)本(ben)次(ci)(ci)價格漲幅最大的產(chan)品(pin)(pin)。若公(gong)(gong)司(si)(si)后續簽訂采(cai)購(gou)(gou)合同并實施，預期(qi)將(jiang)顯著提(ti)升(sheng)公(gong)(gong)司(si)(si)冠脈支架產(chan)品(pin)(pin)的毛利率水平，對公(gong)(gong)司(si)(si)盈利能力(li)有重大積(ji)極影響。